Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity

Leukemia and Lymphoma

Volumn 46, Issue 10, 2005, Pages 1455-1462

  Rizzieri, David A ^a   Wadleigh, Martha ^a   Wikstrand, Carol J ^a   Mann, Karen P ^b   Sen, Filiz ^a   Peterson, Bercedis L ^a   Niedzwiecki, Donna ^a   Proia, Alan D ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lymphoma; Microvessel density; Stroma; Tenascin

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN ANTIBODY; TENASCIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ARTICLE; BONE MARROW METASTASIS; BURKITT LYMPHOMA; CANCER GROWTH; CANCER RELAPSE; CELL ISOLATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MICROVASCULATURE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; STEM CELL TRANSPLANTATION; STROMA CELL;

BLOOD VESSELS; BONE MARROW; DISEASE PROGRESSION; HUMANS; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MICROCIRCULATION; STROMAL CELLS; TENASCIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 26944452074     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500158060     Document Type: Article

References (30)

1. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 1982;49:2112-2135.
2. A Predictive Model for Aggressive non-Hodgkin's Lymphoma. International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Eng J Med 1993;329:987-994.
3. Steele JG, Savolainen TA, Dalton BA, Smith L, Smith GL. Adhesion to laminin and expression of laminin in clonally elated transformed and control sublines from an alveolar epithelial cell strain. Cancer Res 1990;50:3383-3389.
4. Kawamoto T, Shoda J, Asano T, et al. Expression of cyclooxygenase - 2 in the subserosal layer correlates with post surgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 2002;98:427-434.
5. Ranuncolo SM, Matos E, Loria D, et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 2002;94:1483-1491.
6. Ruiter D, Bigenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002;3:35-43.
7. Vacca A, Ribatti D, Fanelli M, et al. Expression of tenascin is related to histologic malignancy and angiogenesis in B cell non-Hodgkin's lymphomas. Leuk Lymphoma 1996;22:473-481.
8. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Demmacco F. Angiogenesis spectrum in the stroma. of B cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996;56:45-53.
9. Mackie EJ. Molecules in focus: Tenascin-C. Int J Biochem Cell Biol 1997;29:1133-1137.
10. Canfield AE and Schor AM. Evidence that tenascin and thrombospondin -1 modulate sprouting of endothelial cells. J Cell Sci 1995;108:797-809.
11. Forsberg E, Hirsch E. Frohlich L, et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci USA 1996;93:6594-9.
12. Kostianovsky M, Greco MA, Cangiarella J, Zagzag D. Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions. Ultrastruct Pathol 1997;21:537-544.
13. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant glioma: Phase I trial of results. J Clin Oncol 1998;16:2202-2212.
14. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma associated antigen expression in oligodendroglial neoplasms: tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000;48:1103-1110.
15. Vacca A, Ribatti D, Presta M, et al. Bone Marrow Neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3073.
16. Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B cell NHL. Int J Cancer 2000;85:171-175.
17. Pruneri G, Ponzoni M, Ferreri AJ, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002;118:817-820.
18. Bosari S, Lee AKC, Delellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-761.
19. Guinebretiere JM, LeMonique G, Bahi J, Contesso G. Angiogenesis at risk in breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994;86: 635-636.
20. Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2, and CA IX in NHL. Histopathology 2002;40:253-260.
21. Zagzag D, Friedlander DR, Dosik J, et al. Tenascin C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996;56:182-189.
22. Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I. Expression of Tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 1996;69:445-447.
23. Broll R, Meyer S, Nuber M, Bruch HP. Expression of Tenascin in tumors of the esophagus, small intestine and colorectum. Gen Diagn Pathol 1995;141:111-119.
24. Kusagawa H, Onoda K, Namikawa S, et al. Expression and degradation of Tenascin C in human lung cancers. Br J Cancer 1998;77:98-102.
25. Fine H, Loeffler JS, Kyritsis A, et al. Phase II trial of anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. Proceedings of ASCO 1997;16:#1372.
26. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000;18:600-608.
27. Pazgal I, Zimra Y, Tzabar C, et al. Expression of basic fibroblast growth factor in associated with poor outcome in NHL. Br J. Cancer 2002;86:1770-1775.
28. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum VEGF concentration is associated with poor outcome in NHL. Blood 1997;90:3167-3172.
29. Nishi J, Arimura K, Utsunomiya A, et al. Expression of VEGF in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999;104:482-485.
30. Sezer O, Niemoller K, Kaufmann O, Eucker J, Jacob C, Zavrski I. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001;66:238-244.